Researcher Tweaks T-Cells for Tumors

Posted: Updated:
Nallathamby and his team are developing a double-sided nanoparticle. Nallathamby and his team are developing a double-sided nanoparticle.

A new cutting-edge cancer treatment called CAR T-cell therapy—which requires only a single treatment—is curing patients with certain lymphomas and blood cancers, but researchers are struggling to translate the treatment for solid tumors. National Breast Cancer Awareness Month is coming to a close, but University of Notre Dame researcher Dr. Prakash Nallathamby is holding steadfast to his goal of unleashing the power of CAR T-cells for breast cancer tumors—a disease that has taken two members of his family.

“So it’s personal for me,” says Nallathamby, whose grandmother and aunt died battling breast cancer. “That personal side of it has had a huge impact, and it is a great motivator to see what more we can do to fight this disease.”

CAR T-cell therapy, designed for patients who don’t respond to conventional therapy, has been administered to just two Hoosier patients. The therapy involves taking a patient’s T-cells (a type of immune system cell) and changing them in the laboratory, so they’ll attack cancer cells when injected back into the patient.

Experts call it a cure and the next chapter of cancer treatment, “but the only setback so far seems to be that it’s only applicable for different lymphomas and blood cancers,” says Nallathamby, “so if there’s any way we could use this for solid [tumors], that’d be great.”

Nallathamby, a research assistant professor of aerospace and mechanical engineering and affiliated member of NDnano, has made it his mission to translate T-cell therapy for solid tumors and is first taking aim at breast cancer.

“Right now, when CAR T-cells are used against solid tumors, there have been some really bad results with regard to [the T-cells] being so efficient that the whole tumor bursts, and it leads to something called tumor lysis syndrome [in which large amounts of killed tumor cells release their contents into the bloodstream],” says Nallathamby. “Or [T-cells] target healthy tissue, and they can’t be switched off. If [T-cells] attack the heart or lungs, it kills the patient.”

Nallathamby’s strategy centers on a unique nanoparticle that his team has designed to take control of the powerful T-cells. The nanoparticle’s key feature is its double-sided structure; one end is designed to bind to the surface of the tumor, and the other has a special receptor that captures the CAR T-cells, ensuring the T-cells will only attach to the nanoparticle, therefore, attacking the tumor and not healthy tissue.

Nallathamby is using a special category of T-cells, called universal CAR T-cells (uCAR T-cells). These are commercially-available T-cells, instead of the conventional T-cells that need to be obtained from the patient. Nallathamby says current CAR T-cell treatment requires 20 to 30 days, but because universal T-cells are readily available, they can be administered within two to three days.

Finally, Nallathamby says a nano activator is injected, providing even more control over the T-cells. The nano activator “turns on” the uCAR T-cells and the dosage amount dictates their killing power, so they don’t attack the tumor too quickly and trigger tumor lysis syndrome.

Importantly, as the activator is depleted, the powerful uCAR T-cells are “turned off.” The specially-designed nanoparticles will also release their grip on the tumor after three to four days and are naturally flushed out of the body. This double layer of protection ensures the T-cells don’t cause any negative “off target” effects in the body.

While still in the early stages of development, Nallathamby believes the strategy will also translate well for ovarian and prostate cancer. Nallathamby says CAR T-cells—while extremely powerful—must also be harnessed to avoid the negative effects of such might. He’s confident managing CAR T-cells’ use in tumors with his specially-designed nanoparticles could unlock the treatment for many more cancers and patients.

In addition to his personal connection to breast cancer, Nallathamby says he chose the disease because it’s a robust area of research.
Nallathamby says advances in immunotherapy, such as CAR T-cell treatment, are also important because patients can maintain a more normal lifestyle.
  • Perspectives

    • Is Your Physician Experiencing Burnout?

      All professions experience varying degrees of burnout. Physicians and health professionals, who may treat symptoms of burnout in their patients, are not immune to job burnout and depression. In its latest revision of the International Classification of Diseases, the World Health Organization has officially classified workplace burnout as an occupational phenomenon. According to the Mayo Clinic, job burnout is a special type of work-related stress - a state of physical or emotional...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Photo of Gary City Hall courtesy of the City of Gary

      Gary to Hold Job Fair for Residents

      The City of Gary and the Gary Re-Entry Coalition have partnered to hold a job fair for Gary residents on Wednesday. City officials expect more than 39 employers to participate in the job fair. The annual event will run from 10 a.m. to 3 p.m. at the Gary SouthShore RailCats Stadium. 

    • NSWC Crane is located within Naval Support Activity Crane, one of the largest naval bases in the U.S.

      Military Contract Work To Be Done in Indiana

      Virginia-based Science Applications International Corp. has been awarded a nearly $42 million military contract for work on gun and guided missile systems. The overhaul and repair of  antenna systems for the U.S. Navy will be performed at SAIC locations in Bedford, Crane and Springville, Indiana.

    • The University of Notre Dame is one of the Indiana representatives on the list. (photo courtesy University of Notre Dame)

      Hoosier Companies Among 'Best Places to Work in IT'

      Three Indiana organizations are included in Computerworld's 2019 list of the 100 Best Places to Work in IT. The ranking, which splits the companies among large, medium, and small organizations, is based on company and employee surveys, as well as factors such as benefits, career development and retention.

    • Pet-Friendly Workplaces Rewarding, But Require Thoughtful Policies

      Silicon Valley startups have long touted pet-friendly workplaces, but PetFirst Pet Insurance has been pet-friendly long before most startups were even sketches on a napkin. Over the years, we’ve come to recognize that a pet-friendly workplace is valuable for morale and a favorite perk for new hires – but it also takes good planning and policies. When we were founded in 2004 as a small team, bringing pets to the office was pretty easy. But now we have more than...

    • (Image courtesy of Dickinson Fleet Services.)

      Dickinson Fleet Services Acquires Baltimore Company

      Indianapolis-based Dickinson Fleet Services has announced its acquisition of American Fleet Services of Baltimore, Maryland. American Fleet Services marks Dickinson’s eighth acquisition since 2017 and the second in 2019.